Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy
Objective: to conduct a clinical and economic study of acalabrutinib for the treatment of adult patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy in the Russian Federation.Material and methods. Acalabrutinib and ibrutinib were conside...
Saved in:
| Main Authors: | S. K. Zyryanov, I. N. Dyakov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2024-08-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/1040 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Intermediate Results of Prospective Observational Study: The 2-year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice
by: VI Vorob’ev, et al.
Published: (2019-03-01) -
First-Line Treatment of Mantle-Cell Lymphoma: Analysis of Effectiveness and Cost-Effectiveness
by: KD Kaplanov, et al.
Published: (2018-04-01) -
Mantle Cell Lymphoma of Intestine Presenting as Multiple Lymphomatous Polyposis with Intussusception
by: Meena N. Jadhav, et al.
Published: (2015-01-01) -
Treatment outcomes for patients with newly diagnosed or relapsed/refractory TP53-mutated mantle cell lymphoma: a systematic review and meta-analysisResearch in context
by: Na Zhang, et al.
Published: (2025-07-01) -
A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases
by: Kerry A Rogers, et al.
Published: (2025-04-01)